Patients with advanced hepatocellular carcinoma show no benefit from adding erlotinib to sorafenib

The researchers tested whether adjunct erlotinib, a direct and reversible EGFR tyrosine kinase inhibitor, could have synergistic or additive antitumor effects when used with sorafenib in patients with advanced hepatocellular carcinoma. The approach did not improve overall survival or time to progression according to the study report at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. Read more here.